Page Body

Page Main

Post Main

Post Article

Beth Mole, Ars Technica:

The chief executive of a small pharmaceutical company defended hiking the price of an essential antibiotic by more than 400 percent and told the Financial Times that he thinks “it is a moral requirement to make money when you can.”

Nirmal Mulye, CEO of the small Missouri-based drug company Nostrum Laboratories, raised the price of a bottle of nitrofurantoin from $474.75 to $2,392 last month. The drug is a decades-old antibiotic used to treat urinary-tract infections caused by Escherichia coli and certain other Gram-negative bacteria. The World Health Organization lists nitrofurantoin as an essential medicine.

In an interview with the FT, Mulye went on to say it was also a “moral requirement” to “sell the product for the highest price,” and he explained that he was in “this business to make money.”

In line with this perspective, Mulye took a moment to defend Martin Shkreli, who gained notoriety for buying exclusive rights to another decades-old drug and ruthlessly raised its price by more than 5,000 percent virtually overnight. (Shkreli was sentenced to seven years in prison in March on unrelated fraud charges.)

Paul Ciano

Enjoyed this post?

Subscribe to my feed for the latest updates.